Trovagene Set to Offer Transrenal KRAS Assay on Bio-Rad dPCR System in January | GenomeWeb

Trovagene this week said that it has completed development of its first molecular diagnostic, a transrenal assay for detecting KRAS mutations, and expects to transfer the assay to its CLIA lab next month and offer the test commercially in January.

Trovagene's test will use Bio-Rad's QX100 Droplet Digital PCR system to detect the most prevalent cancer-related KRAS mutations in cell-free nucleic acids from patient urine samples in order to monitor the progression of pancreatic cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.